3月11日，中国生物制药(01177)盘中上涨4.78%，截至13:50，报3.51元/股，成交3.52亿元。
中国生物制药有限公司是一家创新研究和研发驱动型的医药集团，其主要业务包括医药研发、智能化生产以及销售，主要产品包括多种生物药和化学药，特别在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗领域具有优势。公司自从2000年上市以来，在MSCI全球标准指数、恒生指数等多个指数中成为成分股，连续六年入选《制药经理人》的“全球制药企业TOP50”，核心企业正大天晴药业集团、北京泰德制药股份有限公司多年位列中国医药工业企业百强榜，公司产品收入占比逐年提升。
截至2024年中报，中国生物制药营业总收入158.74亿元、净利润30.17亿元。
3月20日，中国生物制药将披露2024财年年报。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.